Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase 4 1Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neuroendocrine Tumors 4Neoplasms 2Acromegaly 2Serotonin Syndrome 1Pituitary Neoplasms 1Pancreatitis 1Pancreatic Intraductal Neoplasms 1Gastro-enteropancreatic neuroendocrine tumor 1Fistula 1Duodenal Neoplasms 1Diarrhea 1Colorectal Neoplasms 1Carcinoid Tumor 1Breast Neoplasms 1Brain Neoplasms 1Adenoma 1

Interventions

Capecitabine 13Fluorouracil 11Oxaliplatin 10Bevacizumab 9Leucovorin 6Irinotecan 6HMPL-013 4Folfox protocol 4Cetuximab 4ferric carboxymaltose 3regorafenib 2gadolinium ethoxybenzyl DTPA 2gadobenic acid 2Triamcinolone 2Standard of Care 2Radiofrequency Ablation 2Pirinitramide 2Morphine 2Esomeprazole 2Analgesia, Epidural 2zidovudine 5'-monophosphate-mannose-albumin conjugate 1sodium phosphate 1raltitrexed 1polyethylene glycol 3350 1iron isomaltoside 1000 1galactosamine-conjugated serum albumin-conjugated-(rhodamine X)20 1gadoteridol 1gadoterate meglumine 1gadodiamide 1gadobutrol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Colorectal Neoplasms × Octreotide × Clear all
NCT00050635 2009-11-19

STOP Trial - Sandostatin LAR Depot Trial for the Optimum Prevention of Chemotherapy Induced Diarrhea

Novartis

Phase 4 Completed
150 enrolled
Gastrointestinal

Diarrhea, Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡